pulmonary

Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis

Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis…

1 week ago

JASCAYD (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China

The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five…

1 month ago